Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

52 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Early phase antitumour clinical trials and palliative medicine.
Virani F, Carey M, Kazmi F, Blagden S, Lord S, Miller M. Virani F, et al. BMJ Support Palliat Care. 2024 Jan 8;13(e3):e780-e781. doi: 10.1136/spcare-2023-004496. BMJ Support Palliat Care. 2024. PMID: 37507202 No abstract available.
A phase I open-label, dose-escalation study of NUC-3373, a targeted thymidylate synthase inhibitor, in patients with advanced cancer (NuTide:301).
Spiliopoulou P, Kazmi F, Aroldi F, Holmes T, Thompson D, Griffiths L, Qi C, Parkes M, Lord S, Veal GJ, Harrison DJ, Coyle VM, Graham J, Jeffry Evans TR, Blagden SP. Spiliopoulou P, et al. Among authors: blagden sp. J Exp Clin Cancer Res. 2024 Apr 2;43(1):100. doi: 10.1186/s13046-024-03010-1. J Exp Clin Cancer Res. 2024. PMID: 38566164 Free PMC article. Clinical Trial.
Cancer Precision-Prevention trial of Metformin in adults with Li Fraumeni syndrome (MILI) undergoing yearly MRI surveillance: a randomised controlled trial protocol.
Dixon-Zegeye M, Shaw R, Collins L, Perez-Smith K, Ooms A, Qiao M, Pantziarka P, Izatt L, Tischkowitz M, Harrison RE, George A, Woodward ER, Lord S, Hawkes L, Evans DG, Franklin J, Hanson H, Blagden SP. Dixon-Zegeye M, et al. Among authors: blagden sp. Trials. 2024 Feb 3;25(1):103. doi: 10.1186/s13063-024-07929-w. Trials. 2024. PMID: 38308321 Free PMC article.
Phase I/II sequencing study of azacitidine, epacadostat, and pembrolizumab in advanced solid tumors.
Luke JJ, Fakih M, Schneider C, Chiorean EG, Bendell J, Kristeleit R, Kurzrock R, Blagden SP, Brana I, Goff LW, O'Hayer K, Geschwindt R, Smith M, Zhou F, Naing A. Luke JJ, et al. Among authors: blagden sp. Br J Cancer. 2023 Jun;128(12):2227-2235. doi: 10.1038/s41416-023-02267-1. Epub 2023 Apr 22. Br J Cancer. 2023. PMID: 37087488 Free PMC article. Clinical Trial.
Additional consensus recommendations for conducting complex innovative trials of oncology agents: a post-pandemic perspective.
Blagden SP, Yu LM, Ellis S, Hughes H, Shaaban A, Fennelly-Barnwell J, Lythgoe MP, Cooper AM, Maignen FM, Buckland SW, Kearns PR, Brown LC; Experimental Cancer Medicine Centres (ECMC) CID trials working group. Blagden SP, et al. Br J Cancer. 2023 Feb;128(3):474-477. doi: 10.1038/s41416-022-02051-7. Epub 2022 Nov 24. Br J Cancer. 2023. PMID: 36434156 Free PMC article.
First-in-human phase I/II, open-label study of the anti-OX40 agonist INCAGN01949 in patients with advanced solid tumors.
Davis EJ, Martin-Liberal J, Kristeleit R, Cho DC, Blagden SP, Berthold D, Cardin DB, Vieito M, Miller RE, Hari Dass P, Orcurto A, Spencer K, Janik JE, Clark J, Condamine T, Pulini J, Chen X, Mehnert JM. Davis EJ, et al. Among authors: blagden sp. J Immunother Cancer. 2022 Oct;10(10):e004235. doi: 10.1136/jitc-2021-004235. J Immunother Cancer. 2022. PMID: 36316061 Free PMC article. Clinical Trial.
52 results